ketamine has been researched along with Pain, Intractable in 99 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Pain, Intractable: Persistent pain that is refractory to some or all forms of treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double blind, cross over study was designed to evaluate the effect of ketamine on spinal morphine analgesia in terminal cancer pain patients." | 9.08 | Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. ( Chang, JY; Ho, ST; Wong, CS; Yang, CY, 1996) |
| " Neuropathic pain represents the first indication to use ketamine, followed, with a good to moderate utility, by other situations (fibromyalgia, complex regional pain syndrome, central neuropathic pain, peripheral neuropathic pain, nociceptive pain, sensitization, opioid withdrawal, palliative care, depression)." | 8.12 | Ketamine in chronic pain: A Delphi survey. ( Amodéo, JM; André, G; Barmaki, M; Collard, O; Colomb, C; Créac'h, C; de Chazeron, I; de Montgazon, G; Deleens, R; Delorme, C; Dixneuf, V; Dy, L; Gaillard, J; Gov, C; Kieffer, X; Lanteri-Minet, M; Le Borgne, JM; Le Caër, F; Maamar, F; Maindet, C; Marcaillou, F; Morel, V; Pickering, G; Plantevin, F; Pluchon, YM; Riant, T; Rioult, B; Rostaing, S; Salvat, E; Sep Hieng, V; Sorel, M; Vergne-Salle, P; Voute, M, 2022) |
| "The objective of this study was to assess the effectiveness of a low-dose intravenous S-ketamine treatment on refractory pain in patients with Complex Regional Pain Syndrome (CRPS)." | 8.02 | Effect of intravenous low-dose S-ketamine on pain in patients with Complex Regional Pain Syndrome: A retrospective cohort study. ( Bharwani, KD; de Vos, CC; Dirckx, M; Frankema, SPG; Huygen, FJPM; Mangnus, TJP; Stronks, DL, 2021) |
| "Four patients with postherpetic neuralgia had their pain alleviated by epidural administration of ketamine." | 7.71 | [Usefulness of epidural administration of ketamine for relief of postherpetic neuralgia]. ( Ikeda, M; Machida, K; Mikawa, Y; Mizuno, J; Sugimoto, S, 2001) |
| "What questions did we seek to answer? Chronic pain is a common problem with limited effective treatments." | 5.91 | Therapeutic effects of 7- to 14-day subanesthetic ketamine infusions for chronic pain on standardized psychiatric measures. ( Marzoughi, S; Ong, M; Ripsman, D, 2023) |
| "Pain is common in advanced cancer is often refractory to standard treatment." | 5.62 | Subanesthetic ketamine in the ambulatory setting for refractory cancer pain: a 6-year retrospective at a cancer center. ( Benkli, B; Chung, M; Huh, B; Qing, Y; Roldan, C; Wang, J, 2021) |
| "Opioid-induced hyperalgesia is a paradoxical adverse effect of opioid therapy with unclear strategies for its treatment and management." | 5.48 | The Enigma of Low-Dose Ketamine for Treatment of Opioid-Induced Hyperalgesia in the Setting of Psychosocial Suffering and Cancer-Associated Pain. ( Atayee, RS; Mesarwi, P; Willeford, A; Winters, KD, 2018) |
| "Among 55 cases (51 patients, neuropathic pain 60%), the mean effective oral dose was 2 mg/kg." | 5.42 | Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 patients. ( Bellanger, A; Bourgeois, P; Coutaux, A; Magneux, C; Marchetti, F; Mion, G, 2015) |
| "To estimate the level of bone cancer pain, the number of pain-related behaviours induced by repeated applications of a von Frey monofilament (0." | 5.33 | Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain. ( Aoe, T; Kozikowski, A; Neale, JH; Saito, O; Sarva, J; Yamamoto, T, 2006) |
| "A double blind, cross over study was designed to evaluate the effect of ketamine on spinal morphine analgesia in terminal cancer pain patients." | 5.08 | Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. ( Chang, JY; Ho, ST; Wong, CS; Yang, CY, 1996) |
| "This nationwide, multicenter, prospective cohort study included patients in France with treatment-refractory chronic pain who received repeated ketamine administration, over 1 year, according to ketamine use in their pain clinic." | 4.31 | Assessment of Initial Depressive State and Pain Relief With Ketamine in Patients With Chronic Refractory Pain. ( Lambert, C; Pereira, B; Pickering, G; Voute, M, 2023) |
| "This prospective, multicentre, observational trial collected data regarding demographics, pain characteristics, pain score assessment within the first 48 hours of ketamine administration, tolerance and satisfaction from 38 patients aged 2-24 years prescribed with ketamine as an adjuvant antalgic for refractory cancer pain in 10 French paediatric oncology centres." | 4.12 | Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study. ( Bertrand, A; Cojean, N; Courade, M; Dugue, S; Guerrini-Rousseau, L; Lervat, C; Levy, D; Marec-Berard, P; Pagnier, A; Piguet, C; Ribrault, A; Schmitt, C; Thouvenin, S, 2022) |
| " Neuropathic pain represents the first indication to use ketamine, followed, with a good to moderate utility, by other situations (fibromyalgia, complex regional pain syndrome, central neuropathic pain, peripheral neuropathic pain, nociceptive pain, sensitization, opioid withdrawal, palliative care, depression)." | 4.12 | Ketamine in chronic pain: A Delphi survey. ( Amodéo, JM; André, G; Barmaki, M; Collard, O; Colomb, C; Créac'h, C; de Chazeron, I; de Montgazon, G; Deleens, R; Delorme, C; Dixneuf, V; Dy, L; Gaillard, J; Gov, C; Kieffer, X; Lanteri-Minet, M; Le Borgne, JM; Le Caër, F; Maamar, F; Maindet, C; Marcaillou, F; Morel, V; Pickering, G; Plantevin, F; Pluchon, YM; Riant, T; Rioult, B; Rostaing, S; Salvat, E; Sep Hieng, V; Sorel, M; Vergne-Salle, P; Voute, M, 2022) |
| "The objective of this study was to assess the effectiveness of a low-dose intravenous S-ketamine treatment on refractory pain in patients with Complex Regional Pain Syndrome (CRPS)." | 4.02 | Effect of intravenous low-dose S-ketamine on pain in patients with Complex Regional Pain Syndrome: A retrospective cohort study. ( Bharwani, KD; de Vos, CC; Dirckx, M; Frankema, SPG; Huygen, FJPM; Mangnus, TJP; Stronks, DL, 2021) |
| "A 36-year-old female with metastatic breast cancer involving bones, liver, lung, and pleura/chest wall with worsening back pain received weight-based intravenous (IV) ketamine and was transitioned to oral ketamine for cancer-related neuropathic pain." | 3.80 | Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain. ( Amin, P; Atayee, R; Roeland, E, 2014) |
| "Four patients with postherpetic neuralgia had their pain alleviated by epidural administration of ketamine." | 3.71 | [Usefulness of epidural administration of ketamine for relief of postherpetic neuralgia]. ( Ikeda, M; Machida, K; Mikawa, Y; Mizuno, J; Sugimoto, S, 2001) |
| " There was almost twice the incidence of adverse events worse than baseline in the ketamine group after day 1 (incidence rate ratio, 1." | 2.77 | Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. ( Agar, M; Currow, DC; Eckermann, S; Fazekas, B; Hardy, J; Plummer, J; Quinn, S; Rowett, D; Spruyt, O, 2012) |
| "This multi-centre study of adjuvant "burst" ketamine in palliative care in-patients documents its effectiveness, duration of pain relief, and adverse effects (AE) profile." | 2.75 | The effectiveness and adverse effects profile of "burst" ketamine in refractory cancer pain: The VCOG PM 1-00 study. ( Ashby, M; Brumley, D; Good, P; Howell, D; Jackson, K; Petersen, J; Pisasale, M; Wein, S; Woodruff, R, 2010) |
| "Guidelines for cancer pain management include nonsteroidal antiinflammatory drugs with opioids administered in a time-contingent manner." | 2.69 | Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. ( Lauretti, GR; Lima, IC; Pereira, NL; Prado, WA; Reis, MP, 1999) |
| "48 terminal cancer patients suffering from chronic pain." | 2.69 | Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. ( Gomes, JM; Lauretti, GR; Pereira, NL; Reis, MP, 1999) |
| "Ketamine is a medication with evidence of efficacy in the treatment of chronic pain." | 2.49 | Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. ( Bredlau, AL; Dworkin, RH; Korones, DN; Thakur, R, 2013) |
| "What questions did we seek to answer? Chronic pain is a common problem with limited effective treatments." | 1.91 | Therapeutic effects of 7- to 14-day subanesthetic ketamine infusions for chronic pain on standardized psychiatric measures. ( Marzoughi, S; Ong, M; Ripsman, D, 2023) |
| "Pain is common in advanced cancer is often refractory to standard treatment." | 1.62 | Subanesthetic ketamine in the ambulatory setting for refractory cancer pain: a 6-year retrospective at a cancer center. ( Benkli, B; Chung, M; Huh, B; Qing, Y; Roldan, C; Wang, J, 2021) |
| "Ketamine is a fast-acting N-methyl-D-aspartate (NMDA) receptor antagonist that has been emerging as an effective medication for pain alleviation." | 1.62 | Low-dose ketamine as an adjuvant for pain control in a cancer patient: a case report. ( Fattakhov, E; Galea, J; Kaur, G; Patel, S; Singh, AB; Tatachar, V, 2021) |
| "The burden of chronic headache disorders in the United States is substantial." | 1.48 | Ketamine for Refractory Headache: A Retrospective Analysis. ( Dayan, AC; Hernandez, MG; Lauritsen, CG; Rangavajjula, A; Schwenk, ES; Silberstein, SD; Torjman, MC; Viscusi, ER; Young, W, 2018) |
| "Opioid-induced hyperalgesia is a paradoxical adverse effect of opioid therapy with unclear strategies for its treatment and management." | 1.48 | The Enigma of Low-Dose Ketamine for Treatment of Opioid-Induced Hyperalgesia in the Setting of Psychosocial Suffering and Cancer-Associated Pain. ( Atayee, RS; Mesarwi, P; Willeford, A; Winters, KD, 2018) |
| "Refractory migraine is a challenging condition with great impact on health related quality of life." | 1.43 | Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. ( Ashina, S; Lauritsen, C; Lipton, RB; Mazuera, S, 2016) |
| "Among 55 cases (51 patients, neuropathic pain 60%), the mean effective oral dose was 2 mg/kg." | 1.42 | Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 patients. ( Bellanger, A; Bourgeois, P; Coutaux, A; Magneux, C; Marchetti, F; Mion, G, 2015) |
| "For difficult to treat neuropathic pain from cancer, adjuvant analgesics are often used with opioids." | 1.38 | Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain. ( Kajiume, T; Karakawa, S; Kawaguchi, H; Kobayakawa, M; Kobayashi, M; Nakanuno, R; Ogura, T; Oshita, K; Sato, T; Sera, Y; Taguchi, S, 2012) |
| "He complained of refractory pain in the lower back and lower extremities despite high-dose opioid treatment based on the WHO ladder." | 1.37 | Intrathecal neurolytic block in a patient with refractory cancer pain. ( Watanabe, A; Yamakage, M, 2011) |
| " Optimal dosing titration, duration of initial treatment, and the role of maintenance ketamine need to be further elucidated." | 1.37 | The use of ketamine in severe cases of refractory pain syndromes in the palliative care setting: a case series. ( Holahan, T; Kerr, C; Milch, R, 2011) |
| "We describe a case of opioid-refractory pain that responded to a low-dose IV infusion of ketamine in the inpatient setting." | 1.35 | Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient. ( Fitzgibbon, DR; Grande, LA; O'Donnell, BR; Terman, GW, 2008) |
| "In children with advanced stages of cancer, pain control remains inadequate in many patients and a solution to this problem is sorely lacking." | 1.34 | Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. ( Finkel, JC; Pestieau, SR; Quezado, ZM, 2007) |
| "Twelve patients with intractable cancer pain received a test dose of 5-10 mg of ketamine, a strong NMDA antagonist, in order to determine their response and tolerance to the drug." | 1.33 | Successful use of ketamine for intractable cancer pain. ( Body, JJ; Lossignol, DA; Obiols-Portis, M, 2005) |
| "To estimate the level of bone cancer pain, the number of pain-related behaviours induced by repeated applications of a von Frey monofilament (0." | 1.33 | Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain. ( Aoe, T; Kozikowski, A; Neale, JH; Saito, O; Sarva, J; Yamamoto, T, 2006) |
| " The rationale for this treatment, along with dosing guidelines and possible drawbacks, is discussed." | 1.32 | Ketamine patient-controlled analgesia for dysesthetic central pain. ( Cohen, SP; DeJesus, M, 2004) |
| "We report two cases of refractory pain in a spinal disease." | 1.30 | [Ketamine infusion therapy for refractory neuralgia in spinal disease: report of two cases]. ( Enomoto, T; Matsuda, W; Matsumura, A; Miyabe, M; Nose, T; Suga, A; Toyooka, H, 1999) |
| "Two patients with far-advanced cancer, near death, who were experiencing excruciating and intractable pain that was poorly responsive to rapidly escalating doses of morphine and hydromorphone were treated with low-dose intravenous ketamine (0." | 1.30 | Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. ( Fine, PG, 1999) |
| "A case of phantom limb pain, which had not successfully responded to a long list of medical therapy or neurosurgery, is presented." | 1.29 | [Ketamine in the management of intractable phantom pain]. ( Borgbjerg, FM; Franks, JF; Mikkelsen, SS; Olesen, AS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.02) | 18.7374 |
| 1990's | 13 (13.13) | 18.2507 |
| 2000's | 34 (34.34) | 29.6817 |
| 2010's | 34 (34.34) | 24.3611 |
| 2020's | 16 (16.16) | 2.80 |
| Authors | Studies |
|---|---|
| Murakami, S | 1 |
| Asada, T | 1 |
| Kubota, T | 2 |
| Kawakami, H | 1 |
| Kokubun, H | 1 |
| Uezono, Y | 1 |
| Forth, N | 1 |
| Nguyen, M | 1 |
| Grech, A | 1 |
| Voute, M | 2 |
| Riant, T | 1 |
| Amodéo, JM | 1 |
| André, G | 1 |
| Barmaki, M | 1 |
| Collard, O | 1 |
| Colomb, C | 1 |
| Créac'h, C | 1 |
| Deleens, R | 1 |
| Delorme, C | 1 |
| de Montgazon, G | 1 |
| Dixneuf, V | 1 |
| Dy, L | 1 |
| Gaillard, J | 1 |
| Gov, C | 1 |
| Kieffer, X | 1 |
| Lanteri-Minet, M | 1 |
| Le Borgne, JM | 1 |
| Le Caër, F | 1 |
| Maamar, F | 1 |
| Maindet, C | 1 |
| Marcaillou, F | 1 |
| Plantevin, F | 1 |
| Pluchon, YM | 1 |
| Rioult, B | 1 |
| Rostaing, S | 1 |
| Salvat, E | 1 |
| Sep Hieng, V | 1 |
| Sorel, M | 1 |
| Vergne-Salle, P | 1 |
| Morel, V | 1 |
| de Chazeron, I | 1 |
| Pickering, G | 2 |
| Chang, J | 1 |
| Edmonds, KP | 2 |
| Atayee, RS | 3 |
| Lambert, C | 1 |
| Pereira, B | 1 |
| Marzoughi, S | 1 |
| Ripsman, D | 1 |
| Ong, M | 1 |
| Winegarden, JA | 1 |
| Carr, DB | 1 |
| Bradshaw, YS | 1 |
| Pushparaj, H | 1 |
| Bhatia, A | 1 |
| Zhu, M | 1 |
| Whittaker, AK | 1 |
| Jiang, X | 1 |
| Tang, R | 1 |
| Li, X | 1 |
| Xu, W | 1 |
| Fu, C | 1 |
| Smith, MT | 1 |
| Han, FY | 1 |
| Ehrman, S | 1 |
| Houchard, G | 1 |
| Kullgren, J | 1 |
| Chung, M | 1 |
| Benkli, B | 1 |
| Roldan, C | 1 |
| Qing, Y | 1 |
| Wang, J | 1 |
| Huh, B | 1 |
| Patel, S | 1 |
| Tatachar, V | 1 |
| Singh, AB | 1 |
| Galea, J | 1 |
| Fattakhov, E | 1 |
| Kaur, G | 1 |
| Ikomey, GM | 1 |
| Mbakam, CH | 1 |
| Assoumou, MCO | 1 |
| Brandon, JG | 1 |
| Mesembe, M | 1 |
| Mbamyah, EL | 1 |
| Murphy, E | 1 |
| Tagny, CT | 1 |
| Fernandes, M | 1 |
| Schelotto, M | 1 |
| Doldi, PM | 1 |
| Milani, G | 1 |
| Ariza Manzano, AA | 1 |
| Perera Valdivia, D | 1 |
| Winter Matos, AM | 1 |
| Hamdy Abdelrahim, Y | 1 |
| Hamad Bek, SA | 1 |
| Benitez, BK | 1 |
| Romanelli Tavares, VL | 1 |
| Basendwah, AM | 1 |
| Albuquerque Sousa, LH | 1 |
| Xavier, NF | 1 |
| Zertuche Maldonado, T | 1 |
| Toyomi de Oliveira, S | 1 |
| Chaker, M | 1 |
| Menon Miyake, M | 1 |
| Uygur Kucukseymen, E | 1 |
| Waqar, K | 1 |
| Alkhozondar, OMJ | 1 |
| Bernardo da Silva, R | 1 |
| Droppelmann, G | 1 |
| Vaz de Macedo, A | 1 |
| Nakamura, R | 1 |
| Fregni, F | 1 |
| Portugal, F | 1 |
| Araújo, A | 1 |
| Silva, C | 1 |
| Campos, M | 1 |
| Valentim, A | 1 |
| Mangnus, TJP | 1 |
| Dirckx, M | 1 |
| Bharwani, KD | 1 |
| de Vos, CC | 1 |
| Frankema, SPG | 1 |
| Stronks, DL | 1 |
| Huygen, FJPM | 1 |
| Mulder, DJ | 1 |
| Sherlock, ME | 1 |
| Lysecki, DL | 1 |
| Hakim, RC | 1 |
| Schwenk, ES | 1 |
| Dayan, AC | 1 |
| Rangavajjula, A | 1 |
| Torjman, MC | 1 |
| Hernandez, MG | 1 |
| Lauritsen, CG | 1 |
| Silberstein, SD | 1 |
| Young, W | 1 |
| Viscusi, ER | 1 |
| Willeford, A | 1 |
| Winters, KD | 1 |
| Mesarwi, P | 1 |
| Courade, M | 1 |
| Bertrand, A | 1 |
| Guerrini-Rousseau, L | 1 |
| Pagnier, A | 1 |
| Levy, D | 1 |
| Lervat, C | 1 |
| Cojean, N | 1 |
| Ribrault, A | 1 |
| Dugue, S | 1 |
| Thouvenin, S | 1 |
| Piguet, C | 1 |
| Schmitt, C | 1 |
| Marec-Berard, P | 1 |
| Jackson, K | 6 |
| Franco, M | 2 |
| William, L | 2 |
| Poon, P | 3 |
| Pisasale, M | 3 |
| Kenner, D | 1 |
| Brumley, D | 3 |
| Mewett, G | 1 |
| Ashby, M | 4 |
| Viney, M | 1 |
| Kerr, D | 1 |
| Leppert, W | 1 |
| Neri, CM | 1 |
| Pestieau, SR | 2 |
| Darbari, DS | 1 |
| Hardy, J | 3 |
| Quinn, S | 2 |
| Fazekas, B | 2 |
| Eckermann, S | 2 |
| Agar, MR | 2 |
| Spruyt, O | 4 |
| Rowett, D | 2 |
| Currow, D | 1 |
| Mion, G | 4 |
| Marchetti, F | 2 |
| Samama, CM | 1 |
| Bredlau, AL | 1 |
| Thakur, R | 1 |
| Korones, DN | 1 |
| Dworkin, RH | 1 |
| Le, B | 1 |
| Philip, J | 2 |
| Bell, RF | 2 |
| Jaksch, W | 1 |
| Kalso, EA | 1 |
| Le, BH | 1 |
| Amin, P | 1 |
| Roeland, E | 1 |
| Atayee, R | 1 |
| Coutaux, A | 1 |
| Bellanger, A | 1 |
| Magneux, C | 1 |
| Bourgeois, P | 1 |
| Waldfogel, JM | 1 |
| Nesbit, S | 1 |
| Cohen, SP | 2 |
| Dy, SM | 1 |
| Lauritsen, C | 1 |
| Mazuera, S | 1 |
| Lipton, RB | 1 |
| Ashina, S | 1 |
| Hanaoka, K | 3 |
| Arita, H | 3 |
| Nagase, M | 1 |
| Ide, Y | 1 |
| Tagami, M | 1 |
| Hayashida, M | 2 |
| Grande, LA | 1 |
| O'Donnell, BR | 1 |
| Fitzgibbon, DR | 1 |
| Terman, GW | 1 |
| Zimmer, C | 1 |
| Treschan, TA | 1 |
| Meier, S | 1 |
| Nosch, M | 1 |
| Vranken, JH | 3 |
| Kapural, L | 1 |
| Stanton-Hicks, M | 1 |
| Platt, T | 1 |
| Elsewaisy, O | 1 |
| Slon, B | 1 |
| Monagle, J | 1 |
| Howell, D | 1 |
| Petersen, J | 1 |
| Good, P | 1 |
| Wein, S | 1 |
| Woodruff, R | 1 |
| Sato, C | 1 |
| Okabe, T | 1 |
| Nakanishi, K | 1 |
| Sakamoto, A | 1 |
| Quibell, R | 1 |
| Prommer, EE | 1 |
| Mihalyo, M | 1 |
| Twycross, R | 1 |
| Wilcock, A | 1 |
| Watanabe, A | 1 |
| Yamakage, M | 1 |
| Kerr, C | 1 |
| Holahan, T | 1 |
| Milch, R | 1 |
| Patil, S | 1 |
| Anitescu, M | 1 |
| Currow, DC | 2 |
| Hesselink, JM | 1 |
| Kopsky, DJ | 1 |
| Salas, S | 1 |
| Frasca, M | 1 |
| Planchet-Barraud, B | 1 |
| Burucoa, B | 1 |
| Pascal, M | 1 |
| Lapiana, JM | 1 |
| Hermet, R | 1 |
| Castany, C | 1 |
| Ravallec, F | 1 |
| Loundou, A | 1 |
| Auquier, P | 1 |
| Duffaud, F | 1 |
| Baumstarck, K | 1 |
| Kajiume, T | 1 |
| Sera, Y | 1 |
| Nakanuno, R | 1 |
| Ogura, T | 1 |
| Karakawa, S | 1 |
| Kobayakawa, M | 1 |
| Taguchi, S | 1 |
| Oshita, K | 1 |
| Kawaguchi, H | 1 |
| Sato, T | 1 |
| Kobayashi, M | 1 |
| MacKintosh, D | 1 |
| Brady, A | 1 |
| Carr, S | 1 |
| Pirrello, RD | 1 |
| Plummer, J | 1 |
| Agar, M | 1 |
| Uchida, K | 1 |
| Shimazaki, M | 1 |
| Egawa, H | 1 |
| Motojima, F | 1 |
| Fujimaki, K | 1 |
| Hamaguchi, S | 1 |
| Okuda, Y | 1 |
| Kitajima, T | 1 |
| Slatkin, NE | 1 |
| Rhiner, M | 1 |
| Mercadante, S | 2 |
| Villari, P | 1 |
| Ferrera, P | 1 |
| Arcuri, E | 2 |
| van der Vegt, MH | 2 |
| Kal, JE | 1 |
| Kruis, MR | 2 |
| DeJesus, M | 1 |
| Koulmann, P | 1 |
| de Saint-Maurice, G | 1 |
| Gnaho, A | 1 |
| Saïssy, JM | 1 |
| Laufer, M | 1 |
| Schippel, P | 1 |
| Wild, L | 1 |
| Olthoff, D | 1 |
| Tsui, BC | 1 |
| Davies, D | 1 |
| Desai, S | 1 |
| Malherbe, S | 1 |
| Lossignol, DA | 1 |
| Obiols-Portis, M | 1 |
| Body, JJ | 1 |
| Shimoyama, N | 1 |
| Akizuki, A | 1 |
| Takahashi, H | 1 |
| Shimoyama, M | 1 |
| Fukuda, K | 1 |
| Fukunaga, A | 1 |
| Meno, A | 1 |
| Sato, K | 1 |
| Tarui, K | 1 |
| Kaneko, Y | 1 |
| Goodchild, C | 1 |
| Benrath, J | 1 |
| Scharbert, G | 1 |
| Gustorff, B | 1 |
| Adams, HA | 1 |
| Kress, HG | 2 |
| Akin Takmaz, S | 1 |
| Inan, N | 1 |
| Günal, S | 1 |
| Kaymak, C | 1 |
| Sakalli, M | 1 |
| Dikmen, B | 1 |
| Dijkgraaf, MG | 1 |
| van Dasselaar, NT | 1 |
| Miyata, A | 1 |
| Kozek, SA | 1 |
| Sator-Katzenschlager, S | 1 |
| Sandroni, P | 1 |
| Davis, MD | 1 |
| Saito, O | 1 |
| Aoe, T | 1 |
| Kozikowski, A | 1 |
| Sarva, J | 1 |
| Neale, JH | 1 |
| Yamamoto, T | 1 |
| Chung, WJ | 1 |
| Pharo, GH | 1 |
| Ben-Ari, A | 1 |
| Lewis, MC | 1 |
| Davidson, E | 1 |
| Finkel, JC | 1 |
| Quezado, ZM | 1 |
| Okon, T | 1 |
| Koffler, SP | 1 |
| Hampstead, BM | 1 |
| Irani, F | 1 |
| Tinker, J | 1 |
| Kiefer, RT | 1 |
| Rohr, P | 1 |
| Schwartzman, RJ | 1 |
| Kern, D | 1 |
| Pelle-Lancien, E | 1 |
| Luce, V | 1 |
| Bouhassira, D | 1 |
| Mankowitz, E | 1 |
| Brock-Utne, JG | 1 |
| Cosnett, JE | 1 |
| Green-Thompson, R | 1 |
| Bushnell, TG | 1 |
| Craig, J | 1 |
| Franks, JF | 1 |
| Olesen, AS | 1 |
| Mikkelsen, SS | 1 |
| Borgbjerg, FM | 1 |
| Notcutt, WG | 1 |
| Yang, CY | 1 |
| Wong, CS | 1 |
| Chang, JY | 1 |
| Ho, ST | 1 |
| Coe, C | 1 |
| Rüttimann, M | 1 |
| Daniel, L | 1 |
| Matsuda, W | 1 |
| Matsumura, A | 1 |
| Enomoto, T | 1 |
| Nose, T | 1 |
| Suga, A | 1 |
| Miyabe, M | 1 |
| Toyooka, H | 1 |
| Fine, PG | 1 |
| Lauretti, GR | 2 |
| Lima, IC | 1 |
| Reis, MP | 2 |
| Prado, WA | 1 |
| Pereira, NL | 2 |
| Stotz, M | 1 |
| Oehen, HP | 1 |
| Gerber, H | 1 |
| Gomes, JM | 1 |
| Tirelli, W | 1 |
| Casuccio, A | 1 |
| Mizuno, J | 1 |
| Sugimoto, S | 1 |
| Ikeda, M | 2 |
| Machida, K | 1 |
| Mikawa, Y | 1 |
| Martin, P | 1 |
| Hayes, B | 1 |
| Klepstad, P | 1 |
| Borchgrevink, P | 1 |
| Hval, B | 1 |
| Flaat, S | 1 |
| Kaasa, S | 1 |
| Oshima, E | 1 |
| Tei, K | 1 |
| Kayazawa, H | 1 |
| Urabe, N | 1 |
| Sakai, T | 1 |
| Baba, S | 1 |
| Ishihara, H | 1 |
| Matsuki, A | 1 |
| Oyama, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-term Pain Modulation by Intravenous Esketamine in Complex Regional Pain Syndrome: a Non-inferiority Study[NCT05212571] | 60 participants (Anticipated) | Interventional | 2022-04-19 | Enrolling by invitation | |||
| Ketamine for Refractory Chronic Migraine: a Pilot Study[NCT03896256] | Early Phase 1 | 6 participants (Actual) | Interventional | 2019-03-22 | Completed | ||
| A Multi-center Randomized Controlled Trial of Efficacy and Safety of Intravenous Ketamine for Chronic Daily Headaches: The KetHead Study[NCT05306899] | Phase 3 | 56 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis (AKTSS)[NCT03296345] | Phase 2 | 62 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Comparing the Effectiveness of Low-dose Ketamine With Morphine to Treat Pain in Patients With Long Bone Fractures[NCT02430818] | 13 participants (Actual) | Interventional | 2015-04-30 | Terminated (stopped due to were not able to enroll patients to a satisfactory level) | |||
| A Randomized Controlled Trial to Determine the Efficacy of Ketamine as an Adjunct for Pain Management in Patients With Sickle Cell Crisis[NCT03502421] | Phase 3 | 0 participants (Actual) | Interventional | 2018-09-01 | Withdrawn (stopped due to Never IRB approved, no intention to proceed with the study) | ||
| Ketamine Infusion for Acute Sickle Cell crisiS in the Emergency Department[NCT02417298] | 12 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Feasibility) | |||
| Memantine for Post-Operative Pain Control[NCT01041313] | Phase 4 | 120 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | ||
| A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients With Refractory Cancer Pain[NCT03362073] | Phase 2 | 26 participants (Anticipated) | Interventional | 2018-06-01 | Recruiting | ||
| Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash[NCT01566448] | Phase 2 | 30 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine[NCT03096444] | Phase 2 | 13 participants (Actual) | Interventional | 2017-05-23 | Terminated (stopped due to Efficacy was not seen after interim analysis) | ||
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Oral Ketamine for Control of Chronic Pain in Children[NCT01369680] | Phase 1 | 12 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease[NCT01326325] | Phase 3 | 24 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Low-dose Ketamine as Adjuvant Treatment to Morphine in Neuropathic Cancer Pain[NCT01951911] | Phase 3 | 0 participants (Actual) | Interventional | 2013-09-30 | Withdrawn (stopped due to Poor patient recruitment. Vast majority of the patients have exclusions criteria) | ||
| The Use of Ketamine as Rescue Analgesia in the Recovery Room Following Opioid Administration. A Double-blind Randomised Trial in Postoperative Patients.[NCT00163969] | Phase 4 | 40 participants | Interventional | 2002-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Opioid usage for at least one but up to three prior patient visits in the last one year for each patient enrolled in the study was summarized, expressed as morphine equivalents in mg/kg/h, to account for different types of opioids used per patient preference, and then this was compared to the intervention group that received LDK. Percent change in opioid usage (expressed as morphine equivalents in mg/kg/h) is reported). (NCT03296345)
Timeframe: Up to one year prior and after LDK administration on day 1 of the study in the ED
| Intervention | percent change (Mean) |
|---|---|
| Intervention | -15 |
"Percent discharge from the ED for intervention group and for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. Participants were assigned a 0 if discharged or 1 if not discharged." (NCT03296345)
Timeframe: Up to one year prior to receipt of ketamine for the historical control arm/group and up to 18 months for the intervention arm/group
| Intervention | percentage of participants (Number) |
|---|---|
| Intervention | 33 |
| Historical Control | 17 |
Patient pain scores at presentation for the enrolled encounters and for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. At least one but up to three prior visits were averaged and compared to the intervention visit. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: Up to one year prior and on presentation to the ED after LDK administration
| Intervention | Score on a scale (Mean) |
|---|---|
| Intervention | 9.23 |
| Historical Control | 9.08 |
Patient pain scores at time of discharge from the ED/admission to the hospital for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. At least one but up to three prior visits were averaged and compared to the intervention visit. Pain scores post receipt of ketamine are presented for the intervention group. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: At time of discharge from the ED/admission to the hospital (up to one year prior and after LDK administration)
| Intervention | Score on a scale (Mean) |
|---|---|
| Intervention | 7.15 |
| Historical Control | 7.26 |
Length of stay (LOS) in minutes in the ED for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed. (NCT03296345)
Timeframe: Up to one year prior to and after LDK administration on day 1 of the study in the ED
| Intervention | LOS in minutes (Mean) |
|---|---|
| Intervention | 273.5 |
| Historical Control | 217.3 |
Time to 50% pain reduction (pain reported 50% less than baseline) in minutes for at least one but up to three visits prior to receipt of ketamine in the last one year, were assessed as historical controls. Pain was assessed using the faces pain scale which consists of a series of line diagrams of faces with expressions of increasing distress. The score ranges from 0 (no pain) to 10 (the worst pain). (NCT03296345)
Timeframe: Up to one year prior to and after LDK administration on day 1 of the study in the ED
| Intervention | time to 50% pain reduction in minutes (Mean) |
|---|---|
| Intervention | 116.1 |
| Historical Control | 167.3 |
"After receipt of LDK, patients and/or their parents, based on age, filled out a survey based on a Likert scale regarding their agreement (Strongly Disagree to Strongly Agree) with the following statements: Achieved faster pain relief with LDK, Achieved more complete pain relief with LDK, and Desire to receive LDK in a future vaso-occlusive crisis. There is also an area where patients could provide general comments regarding their experience in receiving LDK.~Count of Participants who agree or strongly agree for each question are reported." (NCT03296345)
Timeframe: after LDK administration on day 1 of the study in the ED
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Achieved faster pain relief? | Achieved more complete pain relief? | Desire to receive LDK in the future? | |
| Intervention | 43 | 30 | 49 |
We will monitor for adverse effects and record for changes in vital signs including nausea and vomiting, hypotension, respiratory depression, laryngospasm, and emotional and psychological effects (emergence reactions). (NCT02430818)
Timeframe: 60 minutes
| Intervention | participants (Number) |
|---|---|
| Ketamine | 1 |
| Morphine | 1 |
Study outcomes involve change in participants' pain as measured by a visual analog scale. The scale is a 10 inch line from 0 to 10 inches with 10 being the most pain and 0 being no pain. There are no units on the scale; it is just a straight line from no pain (0) to the worst pain (10). We assessed at o, 15, and 60 minutes but only scored the VAS at 60 minutes. (NCT02430818)
Timeframe: At 0 minutes and 60 minutes
| Intervention | score on a scale (Median) |
|---|---|
| Ketamine | 4 |
| Morphine | 4 |
Patients will be assessed to determine whether the participant would consider using the drug given to them for pain relief in the future. It was measured on a likert scale from 1-5 with 1 being did not like and would not use the drug again to 5 being like and would definitely receive the medication again. There are no units. The numbers below are the total number of patients that completed this answer. This was only asked on patients that received medication as if they did not receive medication the answer would not make sense. The median value is the likert value on a scale of 1-5 with the standard deviation. (NCT02430818)
Timeframe: 60 minutes
| Intervention | units on a scale (Median) |
|---|---|
| Ketamine | 4 |
| Morphine | 4 |
Change in pain score as reported at baseline and after the use of ketamine mouthwash on a numeric scale from 0 to 10, with 0 representing no pain and 10 representing the worst pain. (NCT01566448)
Timeframe: 1 hour after baseline
| Intervention | score on a scale (Median) |
|---|---|
| Ketamine | 2 |
Sleep quality, as reported by the subject on a numeric scale (1-10) will be used as a surrogate marker of quality of life with 0 indicating no sleep and 10 indicating the best sleep you have had. (NCT01566448)
Timeframe: Day 1 after start of ketamine mouthwashes
| Intervention | score on a scale (Median) |
|---|---|
| Ketamine | 1 |
Change of topical lidocaine uses in 24 hour period (NCT01566448)
Timeframe: Days 1 after start of ketamine mouthwashes
| Intervention | lidocaine doses per day (Median) |
|---|---|
| Ketamine | 1 |
Change in IV morphine equivalents of opioid requirements (NCT01566448)
Timeframe: Days 1 after start of ketamine mouthwashes
| Intervention | IV morphine equivalents (Median) |
|---|---|
| Ketamine | 12 |
"Peak itch intensity between the vehicle and 4 other active treatments (individual ketamine, amitriptyline, or lidocaine, and KeAmLi-combo). Itch intensity was measured on a 100mm scale visual analog scale for 10 minutes. 0 was weighted with no itch and 100 was weighted with most itch imaginable." (NCT03096444)
Timeframe: 10 minutes
| Intervention | Intensity score (Mean) |
|---|---|
| Topical KeAmLi Combo | 62.7 |
| Topical Ketamine | 63.1 |
| Topical Amitriptyline | 69.2 |
| Topical Lidocaine | 65.8 |
| Topical Vehicle | 61.9 |
Assess mechanical detection and pain thresholds using von Frey filaments stimulators (measured in force mN) to calculate the final threshold as the geometric mean of five series of ascending and descending stimuli. (NCT03096444)
Timeframe: 5 minutes
| Intervention | mN (Mean) | |
|---|---|---|
| Mechanical Detection Threshold | Mechanical Pain Threshold | |
| Topical Amitriptyline | 3.573423965 | 152.4768146 |
| Topical KeAmLi Combo | 3.519376956 | 152.3293608 |
| Topical Ketamine | 3.464204768 | 135.9 |
| Topical Lidocaine | 3.546037659 | 126.9 |
| Topical Vehicle | 3.525692637 | 148.7138273 |
Two standardized quantitative sensory tests are performed to measure warmth detection threshold (assesses the threshold of which warmth sensation is first detected) and heat pain threshold (assesses the threshold at which heat pain sensation is first detected). Measured in change in celsius. (NCT03096444)
Timeframe: 3 minutes
| Intervention | Degrees celsius (Mean) | |
|---|---|---|
| Warm Detection Threshold | Heat Pain Threshold | |
| Topical Amitriptyline | 33.9 | 40.0 |
| Topical KeAmLi Combo | 33.6 | 39.8 |
| Topical Ketamine | 34.0 | 40.0 |
| Topical Lidocaine | 33.7 | 39.4 |
| Topical Vehicle | 33.8 | 39.7 |
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CY-BOCS Baseline | CY-BOCS Day 14 | |
| Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CGI-S Baseline | CGI-S Day 14 | |
| Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| OCD-VAS Baseline | OCD-VAS Day 14 | |
| Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Y-BOCCS Baseline | Y-BOCCS Day 14 | |
| Ketamine Treatment Group | 18.25 | 16.50 |
"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 0 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 0 |
| Ketamine 1.5 mg/kg/Dose | 0 |
Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1
| Intervention | ng/mL (Mean) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 37.5 |
| Ketamine 0.5 mg/kg/Dose | 135 |
| Ketamine 1 mg/kg/Dose | 250 |
According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 3 |
| Ketamine 1 mg/kg/Dose | 3 |
| Ketamine 1.5 mg/kg/Dose | 1 |
"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 2 |
| Ketamine 1.5 mg/kg/Dose | 0 |
9 reviews available for ketamine and Pain, Intractable
| Article | Year |
|---|---|
Topical Ketamine with Other Adjuvants: Underutilized for Refractory Cancer Pain? A Case Series and Suggested Revision of the World Health Organization Stepladder for Cancer Pain.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Humans; Ketamine; Neoplasms; Pain, Intractable; Retrosp | 2020 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Topics: Anemia, Sickle Cell; Anesthetics, Dissociative; Arterial Occlusive Diseases; Drug Tolerance; Excitat | 2013 |
Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature.
Topics: Adult; Analgesics; Child; Clinical Trials as Topic; Humans; Ketamine; Neoplasms; Pain Management; Pa | 2013 |
[Selection of drugs suitable for the treatment of intractable chronic pain patients by using drug challenge tests].
Topics: Alprostadil; Analgesics; Barbiturates; Benzodiazepines; Chronic Disease; Humans; Ketamine; Lidocaine | 2008 |
Ketamine*.
Topics: Anesthesia; Anesthetics, Dissociative; Animals; Excitatory Amino Acid Antagonists; Humans; Ketamine; | 2011 |
[Palliative medicine for advanced gynecological malignancy].
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Bone Neoplasms; Drug Therapy, | 2004 |
Chronic administration of ketamine for analgesia.
Topics: Analgesics; Animals; Chronic Disease; Humans; Ketamine; Neoplasms; Pain, Intractable; Peripheral Ner | 2007 |
Ketamine: an introduction for the pain and palliative medicine physician.
Topics: Adult; Amines; Analgesics; Analgesics, Opioid; Central Nervous System; Cryoglobulinemia; Cyclohexane | 2007 |
Advances in nursing patients with intractable pain.
Topics: Anesthetics, Dissociative; Dextromethorphan; Drug Monitoring; Female; Humans; Ketamine; Male; Middle | 1997 |
11 trials available for ketamine and Pain, Intractable
| Article | Year |
|---|---|
Topics: Analgesics, Opioid; Chronic Pain; Double-Blind Method; Humans; Ketamine; Pain, Intractable; Quality | 2020 |
The effectiveness and adverse effects profile of "burst" ketamine in refractory cancer pain: The VCOG PM 1-00 study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Clinical Protocols; Drug Administration Schedule; Female | 2010 |
Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care.
Topics: Adult; Aged; Analgesics; Biomedical Research; Double-Blind Method; Female; Humans; Infusions, Intrav | 2012 |
Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain.
Topics: Age Factors; Aged; Aged, 80 and over; Analgesics; Dose-Response Relationship, Drug; Double-Blind Met | 2012 |
Analgesic effect of intravenous ATP on postherpetic neuralgia in comparison with responses to intravenous ketamine and lidocaine.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Analgesics; Anesthetics, Dissociative; Anest | 2005 |
Iontophoretic administration of S(+)-ketamine in patients with intractable central pain: a placebo-controlled trial.
Topics: Administration, Cutaneous; Analgesics; Double-Blind Method; Drug Administration Schedule; Female; He | 2005 |
Pharmacological dissection of the paradoxical pain induced by a thermal grill.
Topics: Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagon | 2008 |
Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Anta | 1996 |
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Humans; Ke | 1999 |
Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy.
Topics: Adult; Aged; Analgesia, Epidural; Double-Blind Method; Drug Synergism; Female; Humans; Ketamine; Mal | 1999 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Topics: Adult; Aged; Central Nervous System; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Bl | 2000 |
79 other studies available for ketamine and Pain, Intractable
| Article | Year |
|---|---|
A Successful Case of Switching Treatment from Ketamine to Methadone for Complex Neuropathic Pain.
Topics: Activities of Daily Living; Analgesics, Opioid; Humans; Ketamine; Methadone; Neuralgia; Pain, Intrac | 2022 |
A Case Report of Subanesthetic Ketamine Bolus and Infusion for Opioid Refractory Cancer Pain.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Humans; Ketamine; Neoplasms; Pain, Intractable | 2022 |
Ketamine in chronic pain: A Delphi survey.
Topics: Chronic Pain; Complex Regional Pain Syndromes; Humans; Ketamine; Neuralgia; Pain, Intractable | 2022 |
A National Survey of Institutional Guidelines for the Use of Ketamine, Lidocaine, and Dexmedetomidine for Refractory Pain.
Topics: Analgesics, Opioid; Dexmedetomidine; Double-Blind Method; Humans; Ketamine; Lidocaine; Pain, Intract | 2023 |
Assessment of Initial Depressive State and Pain Relief With Ketamine in Patients With Chronic Refractory Pain.
Topics: Chronic Pain; Cohort Studies; Female; Humans; Ketamine; Male; Middle Aged; Pain, Intractable; Prospe | 2023 |
Therapeutic effects of 7- to 14-day subanesthetic ketamine infusions for chronic pain on standardized psychiatric measures.
Topics: Chronic Pain; Humans; Infusions, Intravenous; Ketamine; Pain Measurement; Pain, Intractable | 2023 |
Behavioural disturbance after intravenous ketamine infusion for treatment of refractory chronic pain.
Topics: Analgesics; Chronic Pain; Humans; Infusions, Intravenous; Ketamine; Pain, Intractable | 2020 |
Use of Microfluidics to Fabricate Bioerodable Lipid Hybrid Nanoparticles Containing Hydromorphone or Ketamine for the Relief of Intractable Pain.
Topics: Analgesics, Opioid; Animals; Drug Compounding; Hydromorphone; Injections, Spinal; Ketamine; Lipids; | 2020 |
Novel Use of Atomized Intravenous Ketamine Solution for the Topical Treatment of Intranasal Mucositis Pain: A Case Report.
Topics: Analgesics; Humans; Ketamine; Mucositis; Pain Management; Pain, Intractable | 2021 |
Subanesthetic ketamine in the ambulatory setting for refractory cancer pain: a 6-year retrospective at a cancer center.
Topics: Analgesics; Cancer Pain; Humans; Ketamine; Neoplasms; Pain, Intractable; Quality of Life; Retrospect | 2021 |
Low-dose ketamine as an adjuvant for pain control in a cancer patient: a case report.
Topics: Analgesics; Analgesics, Opioid; Emergency Service, Hospital; Humans; Ketamine; Male; Neoplasms; Pain | 2021 |
Combination gel of 2% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain - a case report of pain control success.
Topics: Amitriptyline; Analgesics; Drug Combinations; Erythromelalgia; Humans; Ketamine; Male; Pain Manageme | 2021 |
Effect of intravenous low-dose S-ketamine on pain in patients with Complex Regional Pain Syndrome: A retrospective cohort study.
Topics: Analgesics; Complex Regional Pain Syndromes; Humans; Infusions, Intravenous; Ketamine; Pain, Intract | 2021 |
NMDA-receptor Antagonism in Pediatric Pancreatitis: Use of Ketamine and Methadone in a Teenager With Refractory Pain.
Topics: Adolescent; Analgesics; Humans; Ketamine; Male; Methadone; Off-Label Use; Pain Management; Pain Meas | 2018 |
Case Report: Utility of Ketamine, Lidocaine, and Mexiletine as Nonopioid Adjuvants in Complex Cancer-Associated Pain.
Topics: Adult; Analgesics; Analgesics, Opioid; Anesthetics, Local; Cancer Pain; Carcinoma, Squamous Cell; Fe | 2018 |
Ketamine for Refractory Headache: A Retrospective Analysis.
Topics: Adult; Aged; Analgesics; Female; Follow-Up Studies; Headache Disorders; Humans; Infusions, Intraveno | 2018 |
Ketamine for Refractory Headache: A Retrospective Analysis.
Topics: Adult; Aged; Analgesics; Female; Follow-Up Studies; Headache Disorders; Humans; Infusions, Intraveno | 2018 |
Ketamine for Refractory Headache: A Retrospective Analysis.
Topics: Adult; Aged; Analgesics; Female; Follow-Up Studies; Headache Disorders; Humans; Infusions, Intraveno | 2018 |
Ketamine for Refractory Headache: A Retrospective Analysis.
Topics: Adult; Aged; Analgesics; Female; Follow-Up Studies; Headache Disorders; Humans; Infusions, Intraveno | 2018 |
The Enigma of Low-Dose Ketamine for Treatment of Opioid-Induced Hyperalgesia in the Setting of Psychosocial Suffering and Cancer-Associated Pain.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, D | 2018 |
Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study.
Topics: Adolescent; Analgesics; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Humans; Ketamine; | 2022 |
Ketamine and cancer pain: the reports of my death have been greatly exaggerated.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2013 |
Ketamine in the management of cancer pain.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2013 |
Reply to K. Jackson et al and W. Leppert.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2013 |
[Compassionate use of intrathecal ketamine for intractable cancer pain].
Topics: Anesthetics, Dissociative; Humans; Injections, Spinal; Ketamine; Neoplasms; Neuralgia; Pain, Intract | 2013 |
Integrating new evidence about an old drug: growing pains as palliative medicine matures.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2013 |
Critical appraisal of randomized controlled trials: the beginning of thought….
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2014 |
Interpreting the evidence: reply to Spruyt et al.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2014 |
Integrating new evidence about an old drug: authors' reply to Franco et al. and Bell et al.
Topics: Female; Humans; Ketamine; Male; Neoplasms; Pain, Intractable | 2014 |
Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain.
Topics: Adult; Analgesics; Analgesics, Opioid; Breast Neoplasms; Female; Humans; Ketamine; Neuralgia; Pain M | 2014 |
Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 patients.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Anesthetics, Dis | 2015 |
Successful Treatment of Opioid-Refractory Cancer Pain with Short-Course, Low-Dose Ketamine.
Topics: Adult; Analgesics; Analgesics, Opioid; Cancer Pain; Dose-Response Relationship, Drug; Humans; Ketami | 2016 |
Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series.
Topics: Adult; Chronic Disease; Excitatory Amino Acid Antagonists; Female; Humans; Infusions, Intravenous; K | 2016 |
Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient.
Topics: Adult; Analgesics; Analgesics, Opioid; Drug Tolerance; Humans; Ketamine; Liposarcoma; Male; Memantin | 2008 |
[Long-term treatment with oral ketamine. Case report of a female patient with therapy-resistant post-herpetic neuralgia].
Topics: Administration, Oral; Aged; Analgesics; Female; Humans; Ketamine; Long-Term Care; Neuralgia, Posther | 2009 |
Mechanisms and treatment of neuropathic pain.
Topics: Afferent Pathways; Analgesics; Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Tri | 2009 |
What is considered long-term pain relief in chronic pain management? Re: Sigtermans et al., Pain 2009;145:304-311.
Topics: Analgesics; Chronic Disease; Complex Regional Pain Syndromes; Cost-Benefit Analysis; Drug Administra | 2010 |
When managing established osteonecrosis of the jaw, don't forget the not-infrequent chronic refractory pain.
Topics: Chronic Disease; Disease Management; Female; Humans; Jaw Diseases; Ketamine; Middle Aged; Morphine; | 2010 |
Analgesic effect of subanesthetic intravenous ketamine in refractory neuropathic pain: a case report.
Topics: Analgesics; Humans; Injections, Intravenous; Ketamine; Male; Middle Aged; Neuralgia; Pain, Intractab | 2010 |
A case of cancer pain management by long-term intrathecal PCA.
Topics: Adult; Analgesia, Patient-Controlled; Bupivacaine; Female; Humans; Injections, Spinal; Ketamine; Mor | 2010 |
Intrathecal neurolytic block in a patient with refractory cancer pain.
Topics: Analgesics, Opioid; Glycerol; Humans; Injections, Spinal; Ketamine; Male; Middle Aged; Morphine; Ner | 2011 |
The use of ketamine in severe cases of refractory pain syndromes in the palliative care setting: a case series.
Topics: Adult; Aged; Analgesics; Dose-Response Relationship, Drug; Female; Humans; Ketamine; Male; Middle Ag | 2011 |
Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5-year retrospective analysis.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Analgesics; Chronic Pain; Female; Humans; Infusions, Intra | 2012 |
Progressing an evidence-base beyond case series.
Topics: Analgesics; Female; Humans; Ketamine; Male; Pain, Intractable; Palliative Care | 2011 |
Intractable neuropathic pain due to ulnar nerve entrapment treated with cannabis and ketamine 10%.
Topics: Analgesics; Cannabis; Drug Therapy, Combination; Female; Humans; Ketamine; Middle Aged; Neuralgia; P | 2012 |
Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain.
Topics: Analgesics; Anesthetics, Local; Child, Preschool; Fatal Outcome; Female; Humans; Infusions, Intraven | 2012 |
Ketamine: a real-world experience in cancer pain.
Topics: Analgesics; Female; Humans; Ketamine; Male; Pain, Intractable; Palliative Care | 2012 |
Response to ketamine article.
Topics: Analgesics; Biomedical Research; Female; Humans; Infusions, Intravenous; Ketamine; Male; Neoplasms; | 2012 |
[Successful intravenous administration of low dose ketamine for pain caused by erythromelalgia: report of a case].
Topics: Adolescent; Analgesics; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythromelal | 2002 |
[Intrathecal phenol block in a child with cancer pain--a case report].
Topics: Adolescent; Analgesics, Opioid; Anesthesia, Spinal; Bone Neoplasms; Humans; Injections, Intravenous; | 2003 |
Topical ketamine in the treatment of mucositis pain.
Topics: Adult; Analgesics; Carcinoma, Squamous Cell; Excitatory Amino Acid Antagonists; Female; Humans; Keta | 2003 |
Local anesthetic switching for intrathecal tachyphylaxis in cancer patients with pain.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Anesthetics, Local; Bupivacaine; Humans; Injections, | 2004 |
Treatment of neuropathic cancer pain with continuous intrathecal administration of S +-ketamine.
Topics: Aged; Analgesics; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Neoplasms; Pain, Intr | 2004 |
Ketamine patient-controlled analgesia for dysesthetic central pain.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics; Female; Humans; Infusions, Intravenous; Ketamine; | 2004 |
[Uncontrollable pain in intensive care unit: ketamine contribution].
Topics: Aged; Analgesics; Humans; Intensive Care Units; Ketamine; Male; Pain, Intractable | 2004 |
[Treatment of extreme tumour pain with morphine and s-ketamine A case report of an 11-year old girl].
Topics: Analgesics; Analgesics, Opioid; Carboplatin; Child; Dose-Response Relationship, Drug; Drug Therapy, | 2005 |
Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma.
Topics: Administration, Oral; Analgesics, Non-Narcotic; Analgesics, Opioid; Child, Preschool; Codeine; Drug | 2004 |
Successful use of ketamine for intractable cancer pain.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combinati | 2005 |
Subanesthetic ketamine for cancer pain: by insisting on level I/II evidence, do we risk throwing the baby out with the bath water?
Topics: Adult; Analgesics; Anesthetics, Dissociative; Chemotherapy, Adjuvant; Clinical Trials, Phase I as To | 2005 |
Long-term intrathecal S(+)-ketamine in a patient with cancer-related neuropathic pain.
Topics: Analgesics; Clonidine; Drug Tolerance; Humans; Injections, Spinal; Ketamine; Lumbar Vertebrae; Male; | 2005 |
Ketamine combined with morphine for the management of cancer pain in a patient with meperidine tolerance and addiction.
Topics: Adenocarcinoma; Adult; Analgesics; Drug Therapy, Combination; Drug Tolerance; Humans; Ketamine; Male | 2005 |
Successful use of ketamine for intractable burning pain of HTLV-1-associated myelopathy.
Topics: Aged; Analgesics; Female; Humans; Ketamine; Pain, Intractable; Paraparesis, Tropical Spastic | 2005 |
Intrathecal S(+)-ketamine in refractory neuropathic cancer pain.
Topics: Anesthetics, Dissociative; Brain Stem; Gliosis; Humans; Injections, Spinal; Ketamine; Male; Neoplasm | 2006 |
Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option?
Topics: Adolescent; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Drug Combinations; Erythrom | 2006 |
Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain.
Topics: Adrenergic alpha-Agonists; Analgesia; Animals; Bone Neoplasms; Dexmedetomidine; Dizocilpine Maleate; | 2006 |
Successful use of ketamine infusion in the treatment of intractable cancer pain in an outpatient.
Topics: Adenocarcinoma; Adult; Ambulatory Care; Analgesics; Colonic Neoplasms; Female; Humans; Infusions, In | 2007 |
Ketamine as an adjuvant for treatment of cancer pain in children and adolescents.
Topics: Adolescent; Age Factors; Analgesics, Opioid; Child; Child, Preschool; Dose-Response Relationship, Dr | 2007 |
The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome.
Topics: Adult; Anesthetics; Cognition; Female; Follow-Up Studies; Humans; Ketamine; Learning; Male; MMPI; Ne | 2007 |
Epidural ketamine. A preliminary report.
Topics: Epidural Space; Humans; Injections; Ketamine; Pain, Intractable | 1982 |
Response of chronic neuropathic pain syndromes to ketamine: a role for norketamine?
Topics: Humans; Ketamine; Pain; Pain, Intractable | 1995 |
[Ketamine in the management of intractable phantom pain].
Topics: Administration, Oral; Amputation, Surgical; Female; Forearm; Humans; Ketamine; Middle Aged; Pain, In | 1995 |
Transporting patients with overwhelming pain.
Topics: Adult; Analgesia; Female; Humans; Ketamine; Male; Middle Aged; Pain, Intractable; Spinal Neoplasms; | 1994 |
[Infra-anesthetic ketamine dosage in the treatment of neuropathic-type pain].
Topics: Adult; Anesthetics, Dissociative; Humans; Ketamine; Male; Pain, Intractable; Spinal Cord Injuries | 1997 |
[Ketamine infusion therapy for refractory neuralgia in spinal disease: report of two cases].
Topics: Analgesics; Excitatory Amino Acid Antagonists; Female; Humans; Infusions, Intravenous; Ketamine; Mal | 1999 |
Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain.
Topics: Adolescent; Adult; Analgesics; Female; Humans; Ketamine; Neoplasms; Pain, Intractable; Terminal Care | 1999 |
Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain.
Topics: Adolescent; Adult; Analgesics; Female; Humans; Ketamine; Neoplasms; Pain, Intractable; Terminal Care | 1999 |
Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain.
Topics: Adolescent; Adult; Analgesics; Female; Humans; Ketamine; Neoplasms; Pain, Intractable; Terminal Care | 1999 |
Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain.
Topics: Adolescent; Adult; Analgesics; Female; Humans; Ketamine; Neoplasms; Pain, Intractable; Terminal Care | 1999 |
Low-dose subcutaneous ketamine infusion and morphine tolerance.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Drug Administration Schedule; Female; Humans; Ketamine; | 1999 |
Low-dose subcutaneous ketamine infusion and morphine tolerance.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Drug Administration Schedule; Female; Humans; Ketamine; | 1999 |
Low-dose subcutaneous ketamine infusion and morphine tolerance.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Drug Administration Schedule; Female; Humans; Ketamine; | 1999 |
Low-dose subcutaneous ketamine infusion and morphine tolerance.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Drug Administration Schedule; Female; Humans; Ketamine; | 1999 |
Histological findings after long-term infusion of intrathecal ketamine for chronic pain: a case report.
Topics: Aged; Analgesics; Excitatory Amino Acid Antagonists; Female; Humans; Injections, Spinal; Ketamine; P | 1999 |
[Usefulness of epidural administration of ketamine for relief of postherpetic neuralgia].
Topics: Aged; Analgesia, Epidural; Bupivacaine; Drug Therapy, Combination; Female; Herpes Zoster; Humans; In | 2001 |
"Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients.
Topics: Adult; Aged; Analgesics; Female; Humans; Infusions, Intravenous; Ketamine; Male; Medical Audit; Midd | 2001 |
"Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients.
Topics: Adult; Aged; Analgesics; Female; Humans; Infusions, Intravenous; Ketamine; Male; Medical Audit; Midd | 2001 |
"Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients.
Topics: Adult; Aged; Analgesics; Female; Humans; Infusions, Intravenous; Ketamine; Male; Medical Audit; Midd | 2001 |
"Burst" ketamine for refractory cancer pain: an open-label audit of 39 patients.
Topics: Adult; Aged; Analgesics; Female; Humans; Infusions, Intravenous; Ketamine; Male; Medical Audit; Midd | 2001 |
Long-term treatment with ketamine in a 12-year-old girl with severe neuropathic pain caused by a cervical spinal tumor.
Topics: Analgesia, Patient-Controlled; Analgesics; Brain Stem; Cervical Vertebrae; Child; Diazepam; Drug Res | 2001 |
Continuous subcutaneous injection of ketamine for cancer pain.
Topics: Humans; Ketamine; Neoplasms; Pain, Intractable | 1990 |
Sudden diabetes insipidus induced by ketamine infusion.
Topics: Accidental Falls; Accidents, Occupational; Adult; Diabetes Insipidus; Humans; Infusions, Intravenous | 1986 |